Previous Treatment Failure or Default Increased the Risk of Massive Hemoptysis in PTB Patients

2017 ◽  
Vol 05 (02) ◽  
Author(s):  
Xi Liu ◽  
Li Ding ◽  
Jinyu Xia
Keyword(s):  
Treatment Failure ◽  
Previous Treatment ◽  
Massive Hemoptysis

scholarly journals Recurrent or New Symptomatic Cerebral Aneurysm after Previous Treatment

2005 ◽  
Vol 11 (4) ◽  
pp. 341-348 ◽  
Author(s):  
S. Rothemeyer ◽  
D. Lefeuvre ◽  
A. Taylor
Keyword(s):  
Treatment Failure ◽  
Cerebral Aneurysm ◽  
Nerve Palsy ◽  
Cerebral Aneurysms ◽  
Previous Treatment ◽  
Primary Treatment ◽  
The Other ◽  
Endovascular Coiling ◽  
Previously Treated ◽  
Third Cranial Nerve Palsy

With the establishment of endovascular coiling as a successful treatment for symptomatic cerebral aneurysms, attention is now being directed at the durability of this treatment. If this is to be accurately done it will be important to understand the causes of symptomatic aneurysm presentation after previous treatment. In order to assess this we undertook a retrospective review, covering the four year period from 2000 to 2004, of all patients re-presenting with a symptomatic saccular aneurysm after previous treatment. Seven patients were identified, six presenting with subarachnoid haemorrhage (SAH) and one with a third cranial nerve palsy. Three patients had incomplete clipping of their aneurysms and all presented within months of their initial treatment. The other four patients presented between five and 20 years after primary treatment and all were felt to have new cerebral aneurysms. Two of these patients had aneurysms develop at the same location as their previously treated lesions, however these were still felt to be new aneurysms rather than re-growth or recurrence because of their morphology. Based on our findings it would appear that development of a new cerebral aneurysm after clipping is more of a risk than aneurysm recurrence from treatment failure. This will need to be considered when evaluating re-presentation after treatment by either coiling or clipping and more importantly, perhaps we should be directing more attention to preventing disease progression rather than treatment failure.

scholarly journals Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya

2020 ◽  
Author(s):  
Johannes Ndambuki ◽  
Joseph Nzomo ◽  
Lucy Muregi ◽  
Chris Mutuku ◽  
Francis Makokha ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Treatment Outcomes ◽  
Adverse Outcome ◽  
Previous Treatment ◽  
First Line ◽  
Adherence Support ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Lost To Follow Up

Abstract Background Since 2016, patients with rifampicin-susceptible tuberculosis (TB) have been treated with the 6-month first-line regimen, regardless of treatment history. We assessed treatment outcomes of previously treated and new patients in Machakos subcounty, Kenya. Methods We performed a retrospective cohort study in patients started on first-line treatment between 2016 and 2017. Firth's logistic regression was used to estimate the effect of previous treatment on having a programmatic adverse outcome (either lost to follow-up, death, failure) and treatment failure vs treatment success (either cure or completion). Results Of 1024 new and 79 previously treated patients, 88.1% and 74.7% were treated successfully, 6.5% and 7.6% died, 4.2% and 10.1% were lost to follow-up and 1.2% and 7.6% had treatment failure, respectively. Previous treatment predicted having a programmatic adverse outcome (adjusted odds ratio [aOR] 2.4 [95% confidence interval {CI} 1.4 to 4.2]) and treatment failure (aOR 7.3 [95% CI 2.6 to 20.4]) but not mortality. Similar correlations were found in 334 new and previously treated patients with confirmed baseline rifampicin susceptibility. Conclusion Previously treated patients were more at risk of experiencing a poor treatment outcome, mainly lost to follow-up and treatment failure. Adherence support may reduce lost to follow-up. Rifampicin drug susceptibility testing coverage should increase. More robust retreatment regimens may reduce treatment failure.

Effectiveness of brodalumab after previous treatment failure of interleukin‐ 17A inhibitors in patients with psoriasis

2021 ◽  
Author(s):  
Nikolai Loft ◽  
Anne Bregnhøj ◽  
Simon Fage ◽  
Claus Henrik Nielsen ◽  
Christian Enevold ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Previous Treatment ◽  
Interleukin 17A

scholarly journals Loose ends in the eradication of Helicobacter pylori infection

2016 ◽  
Vol 4 (4) ◽  
pp. 178-181
Author(s):  
Armando Peixoto ◽  
Marco Silva ◽  
Rui Gaspar ◽  
Rui Morais ◽  
Rosa Ramalho ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Helicobacter Pylori ◽  
Treatment Failure ◽  
Breath Test ◽  
Eradication Therapy ◽  
Real Life ◽  
Previous Treatment ◽  
Helicobacter Pylori Infection ◽  
Prevention And Treatment

Abstract The eradication of Helicobacter pylori is essential for prevention and treatment of various conditions associated with this infection. However, its effectiveness is limited and influenced by factors linked to the bacteria and the host. In particular, influence of the biotype, smoking, diabetes mellitus, and previous treatment failure in eradication is understudied. Our center proposed to evaluate these aspects in a real life cohort by applying a questionnaire with demographic and lifestyle variables in patients who consecutively underwent urease breath test after the eradication therapy.

Sign in / Sign up

Export Citation Format

Share Document